Cefoxytin - instructions for use, dose, side effects, contraindications

Clinical and pharmacological group: & nbsp

Cephalosporins

Included in the formulation

Anaerocef®

powder w / m in / in

PREBAND PFC, LLC Russia

Cefoxytin

powdersolution w / m in / in

Company DEKO, LLC Russia

АТХ:

J.01.D.C.01 Cefoxytin

Pharmacodynamics:

Cephalosporin antibiotic II generation for parenteral administration.

Has bactericidal action due to inhibition of bacterial cell wall synthesis. Violates the synthesis of the biopolymer peptidoglikana - the main component of the cell wall of bacteria. It inhibits the peptidoglycan transpeptidase, inhibits the activity of the endogenous inhibitor, which leads to activation of murein hydrolase, which cleaves peptidoglycan. Effective against fissile bacteria, in the walls of which the synthesis of peptidoglycan occurs.

Active against gram-negative bacteria: Haemophilus influenzae, Escherichia coli, Salmonella spp., Shigella spp., Enterobacter spp., Proteus mirabilis, Neisseria gonorrhoeae; gram positive bacteria: Staphylococcus spp., Streptococcus spp.; anaerobic bacteria: Bacteroides spp.

Inactive for Pseudomonas spp., most strains Enterococcus spp., many strains Enterobacter cloacae, methicillin-resistant strains Staphylococcus spp. and Listeria monocytogenes.

Resistant to the action of β-lactamases.

Pharmacokinetics:

After intramuscular injection, the maximum concentration in the blood plasma is reached after 30-120 minutes, after intravenous - in 10 minutes. The connection with plasma proteins is 70-80%.

Not exposed to metabolism. Penetrates through the placental barrier, is found in breast milk.

The half-life is 0.7-1.1 hours, in newborns from 7 days - 5.6 hours; from 7 days to 1 month - 2.5 hours; 1-3 months - 1.7 hours.

Elimination by the kidneys.

Indications:

It is used to treat bacterial infections of respiratory tract, pelvic organs, urinary tract, bones and joints, skin and soft tissues, abdominal infections, sepsis, endocarditis caused by sensitive microorganisms. Used to prevent postoperative infectious complications.

ICD-10

I.A30-A49.A40 Streptococcal septicemia

I.A30-A49.A41 Other septicemia

VIII.H65-H75.H66 Purulent and unspecified otitis media

IX.I30-I52.I33 Acute and subacute endocarditis

X.J00-J06.J00 Acute nasopharyngitis (runny nose)

X.J30-J39.J31.1 Chronic nasopharyngitis

X.J30-J39.J31 Chronic rhinitis, nasopharyngitis and pharyngitis

X.J00-J06.J01 Acute Sinusitis

X.J30-J39.J32.9 Chronic sinusitis, unspecified

X.J30-J39.J31.2 Chronic pharyngitis

X.J00-J06.J02 Acute pharyngitis

X.J00-J06.J03 Acute tonsillitis

X.J30-J39.J35.0 Chronic tonsillitis

X.J00-J06.J04 Acute laryngitis and tracheitis

X.J10-J18.J15 Bacterial pneumonia, not elsewhere classified

XI.K65-K67.K65.0 Acute peritonitis

XI.K80-K87.K81.1 Chronic cholecystitis

XI.K80-K87.K81.0 Acute cholecystitis

XI.K80-K87.K83.0 Cholangitis

XII.L00-L08.L01 Impetigo

XII.L00-L08.L02 Abscess of skin, boil and carbuncle

XII.L00-L08.L03 Phlegmon

XII.L00-L08.L08.0 Pyoderma

XIII.M00-M03.M00 Pyogenic arthritis

XIII.M86-M90.M86 Osteomyelitis

XIV.N10-N16.N11 Chronic tubulointerstitial nephritis

XIV.N10-N16.N10 Acute tubulointerstitial nephritis

XIV.N30-N39.N30 Cystitis

XIV.N30-N39.N34 Urethritis and urethral syndrome

XIV.N40-N51.N41 Inflammatory diseases of the prostate

XIV.N70-N77.N70 Salpingitis and oophoritis

XIV.N70-N77.N71.0 Acute inflammatory disease of the uterus

XIV.N70-N77.N72 Inflammatory disease of the cervix

XIV.N70-N77.N73.0 Acute parametritis and pelvic cellulite

XXI.Z20-Z29.Z29.2 Another type of preventive chemotherapy

Contraindications:

Individual intolerance to β-lactam antibiotics: penicillins and cephalosporins.

Carefully:

Imbalance of electrolytes or fluids, severe liver damage, colitis in history.

Pregnancy and lactation:

Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation in cases where the intended benefit exceeds the risk to the fetus and newborn.

Dosing and Administration:

Use in children

Intramuscularly at 30-40 mg / kg; the frequency of administration depends on age:

- premature babies with a body weight of more than 1500 g and a newborn baby of the first week of life - after 12 hours;

- Newborns 1-4 weeks of life - after 8 hours;

- to older children - in 6 or 8 hours.

Adults

Intravenous, spray or drip, 1-2 g every 6-8 hours.

In uncomplicated gonorrhea, including those caused by penicillinase-producing strains: intramuscularly 2 g once, with ingestion of 1 g of probenecid simultaneously or 1 hour later.

In severe infections: intravenously 2 g every 4 hours or 3 g every 6 hours. The daily dose can be increased to 200 mg / kg (but not more than 12 g). If there is a violation of the excretory function of the kidneys, the first dose is 1-2 g, in the future it is necessary to reduce the single dose and increase the intervals between the administrations.

The highest daily dose: 12 g.

The highest single dose: 2 g.

Side effects:

Central and peripheral nervous system: rarely - convulsions.

Hemopoietic system: thrombocytopenia, eosinophilia, leukopenia, an increase in prothrombin index and coagulation time.

Digestive system: nausea, vomiting, diarrhea, increased activity of hepatic enzymes, hepatic or cholestatic jaundice, intestinal dysbacteriosis.

Dermatological reactions: local reactions - compaction at the injection site, candidiasis dermatitis, vulvovaginitis.

urinary system: rarely - the development of hypokalemia.

Allergic reactions.

Overdose:

Nausea, vomiting, diarrhea, neuromuscular excitability, convulsive attacks.

Treatment is symptomatic, hemodialysis.

Interaction:

Simultaneous application with probenecid slows the renal excretion of cefoxitin.

"Loop diuretics" block the tubular secretion of cefoxitin.

Special instructions:

Cefoxytin is not recommended for the treatment of meningitis.

Simultaneous use with ethanol can cause a disulfiram-like reaction.

Instructions

Cefoxytin (Cefoxitinum)